Evidence map›Paper›PMID 42438827›Full record

ArticleiScience2026

Erk inhibitors intercept Erk-mediated negative feedback while imposing cell-cycle arrest and activating p38.

Merav Darash-Yahana, Nadine Soudah, Alexey Baskin, Inbal Levy-Saar, Alexander Levitzki, David Engelberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Merav Darash-YahanaDepartment of Biological Chemistry, The Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Nadine SoudahDepartment of Biological Chemistry, The Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Alexey BaskinDepartment of Biological Chemistry, The Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Inbal Levy-SaarDepartment of Biological Chemistry, The Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Alexander LevitzkiDepartment of Biological Chemistry, The Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
David EngelbergDepartment of Biological Chemistry, The Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The MAP kinases Erk1/2 mediate the oncogenicity of the receptor tyrosine kinase (RTK)-Ras-Raf-MEK cascade. Components of this pathway are often constantly active in cancer, making Erks promising targets for therapy. Yet, while Erks promote cell proliferation, they concomitantly inhibit the upstream pathway's components. Erks' inhibition may reactivate, therefore, proto-oncoproteins, increasing the risk of recurrent disease. We studied the effects of Erks' inhibitors on cells transformed by Erk1

Indexed as

ASN007BVD523 (Ulixertinib)cisplatinerkGDC0994 (Ravoxertinib)MAP kinaseMEKp38SCH772984Temuterkib (LY3214996)

Identifiers

PMID42438827
PMCPMC13356696

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.